Loading...
•
Jun 30, 2021
United Therapeutics Q2 2021 Earnings Report
United Therapeutics reported a strong second quarter in 2021, marked by revenue growth and progress in clinical trials.
Key Takeaways
United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2021, with total revenue growing by 23% year over year to $446.5 million. The company is focused on expanding its medical options for PAH and progressing in phase 3 studies.
Total revenue increased by 23% year over year, reaching $446.5 million.
Tyvaso net revenue grew by 29% year over year.
Net income increased by 61% to $172.6 million.
The NDA for Tyvaso DPI is under review, with FDA action expected in October 2021.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
United Therapeutics provided forward-looking statements regarding the launches of Remunity Pump for Remodulin and Tyvaso for patients with PH-ILD, the timing and success of efforts to obtain FDA approvals for Tyvaso DPI, research and development plans related to the PERFECT and TETON studies of Tyvaso, the ADVANCE studies of ralinepag, and organ transplantation programs.
Positive Outlook
- Prospects following the launches of Remunity Pump for Remodulin.
- Prospects following the launches of Tyvaso for patients with PH-ILD.
- Expectations concerning the timing and success of efforts to obtain the necessary FDA approvals to launch Tyvaso DPI.
- Statements regarding our research and development plans related to the PERFECT and TETON studies of Tyvaso
- Statements regarding our research and development plans related to the ADVANCE studies of ralinepag, and our organ transplantation programs
Challenges Ahead
- The risk that we will not obtain the necessary FDA approvals to launch Tyvaso DPI.
- Uncertainties related to clinical trial outcomes.
- Risks associated with research and development plans.
- Dependence on key products and regulatory approvals.
- Competition from other pharmaceutical companies.
Revenue & Expenses
Visualization of income flow from segment revenue to net income